Alnylam Pharmaceuticals Inc. (ALNY) News

Alnylam Pharmaceuticals Inc. (ALNY): $226.20

-8.20 (-3.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALNY to Watchlist
Sign Up

Industry: Biotech


Ranked

of 381

in industry

Filter ALNY News Items

ALNY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALNY News Highlights

  • ALNY's 30 day story count now stands at 4.
  • Over the past 2 days, the trend for ALNY's stories per day has been choppy and unclear. It has oscillated between 1 and 3.

Latest ALNY News From Around the Web

Below are the latest news stories about ALNYLAM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ALNY as an investment opportunity.

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies London Healthcare Conference on Wednesday, November 16, 2022 at 2:05 pm GMT (9:05 am ET) at the Waldorf Hilton in London Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 at 1:15 pm ET at the Lotte New York Palace Hotel in New York City Evercore ISI 5th Annual

Business Wire | November 9, 2022

Alnylam Pharma (ALNY) Gets a Hold from SVB Securities

In a report released today, Mani Foroohar from SVB Securities maintained a Hold rating on Alnylam Pharma (ALNY - Research Report), with a price target of $145.00. The company's shares closed last Friday at $208.34.Foroohar covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Moderna, and Alnylam Pharma. According to TipRanks, Foroohar has an average return of -15.4% and a 39.41% success rate on recommended stocks. Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $241.13, implying a 15.74% upside from current levels.

Ryan Adist on TipRanks | November 7, 2022

Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Neurocrine (NBIX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alnylam Pharma (ALNY – Research Report), Neurocrine (NBIX – Research Report) and Rigel (RIGL – Research Report) with bullish sentiments. Alnylam Pharma (ALNY) H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Alnylam Pharma today and set a price target of $415.00. The company's shares closed last Tuesday at $213.12. According to TipRanks.

Catie Powers on TipRanks | November 2, 2022

Looking Into Alnylam Pharmaceuticals''s Return On Capital Employed

Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ: ALNY ) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter. In Q2, Alnylam Pharmaceuticals brought in $224.82 million in sales but lost $277.40 million in earnings. Why Is ROCE Significant? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a … Full story available on Benzinga.com

Benzinga | November 2, 2022

Investors ignore increasing losses at Alnylam Pharmaceuticals (NASDAQ:ALNY) as stock jumps 7.3% this past week

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Yahoo | November 2, 2022

Top 10 Stock Picks of Eli Casdin’s Casdin Capital

In this article, we discuss the top 10 stock picks of Eli Casdin’s Casdin Capital. If you want to skip our detailed analysis of Casdin’s investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin’s Casdin Capital. Unprecedented inflation, increasing interest rates, and a worldwide recession pose risks to the 10-year upward […]

Yahoo | October 31, 2022

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY) and Seagen (SGEN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report) and Seagen (SGEN – Research Report). Alnylam Pharma (ALNY) BMO Capital analyst Gary Nachman maintained a Hold rating on Alnylam Pharma today and set a price target of $200.00. The company's shares closed last Friday at $197.76. According to TipRanks.

Catie Powers on TipRanks | October 28, 2022

Alnylam Pharma (ALNY) Receives a Buy from Chardan Capital

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Alnylam Pharma (ALNY - Research Report) today and set a price target of $250.00. The company's shares closed yesterday at $194.00.Nakae covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Axcella Health, and NeuBase Therapeutics. According to TipRanks, Nakae has an average return of 3.3% and a 37.02% success rate on recommended stocks. Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $241.41, representing a 24.44% upside. In a report released yesterday, Needham also reiterated a Buy rating on the stock with a $240.00 price target.

Brian Anderson on TipRanks | October 28, 2022

Needham Sticks to Its Buy Rating for Alnylam Pharma (ALNY)

In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Alnylam Pharma (ALNY - Research Report), with a price target of $240.00. The company's shares opened today at $197.50.Stringer covers the Healthcare sector, focusing on stocks such as Vaxcyte, Alnylam Pharma, and Avidity Biosciences. According to TipRanks, Stringer has an average return of 2.0% and a 42.27% success rate on recommended stocks. Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $239.78.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $236.80 and a one-year low of $117.58.

Howard Kim on TipRanks | October 27, 2022

Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year

CAMBRIDGE, Mass., October 27, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its second place ranking in Science Magazine’s 2022 Top Employer Survey. This marks the fourth year Alnylam was featured as one of the top three companies in the annual survey of more than 6,200 professionals across biotechnology, biopharmaceuticals and related industries.

Yahoo | October 27, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6058 seconds.